



Ectopic spleen and liver hemangioma mimicking metastatic pancreatic neuroendocrine tumor

Christine C. Engler^a, Johannes Lemke^a, Marko Kornmann^a, Thomas F. Barth^b, Stefan A. Schmidt^c, Doris Henne-Brunns^{a,*}

^a Clinic of General and Visceral Surgery, University of Ulm, Albert-Einstein-Allee 23, 89081 Ulm, Germany

^b Institute of Pathology, University of Ulm, Albert-Einstein-Allee 23, 89081 Ulm, Germany

^c Department of Diagnostic and Interventional Radiology, University of Ulm, Albert-Einstein-Allee 23, 89081 Ulm, Germany



ARTICLE INFO

Article history:

Received 18 August 2015

Received in revised form 12 October 2015

Accepted 31 October 2015

Available online 6 November 2015

Keywords:

Intrapancreatic accessory spleen

Pancreatic neuroendocrine tumor

Liver hemangioma

Metastasis

ABSTRACT

Pancreatic tumors comprise benign lesion and malignant lesion, most importantly pancreatic adenocarcinoma, acinar cell carcinoma, neuroendocrine carcinoma or metastasis. Surgical resection provides the only chance for cure for malignant pancreatic tumors. In some cases, surgical resection is performed because a malignant lesion is suspected, however, histopathological examinations eventually reveal a benign lesion. Here, we report the case of a 49-year-old woman, who was initially diagnosed with a neuroendocrine tumor of the pancreas with metastasis to the liver. The patient underwent distal pancreatectomy and atypical liver resection. Surprisingly, however, histopathological examination revealed an intrapancreatic accessory spleen (IPAS) of the pancreatic tail as well as liver hemangioma. This unique case report highlights the impact of extensive preoperative examinations to differentiate benign and malignant pancreatic lesions and, possibly, prevent patients from unnecessary surgery.

© 2015 The Authors. Published by Elsevier Ltd. on behalf of IJS Publishing Group Ltd. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

1. Introduction

Neuroendocrine carcinoma of the pancreas (panNET) represent a rare tumor entity which amount for only 2% of all pancreatic neoplasms [1,2]. panNETs mainly develop in the pancreatic head and about 15–53% of patients suffering from panNETs become symptomatic due to hormone secretion such as insulin or gastrin [3]. The majority of all panNETs show malignant characteristics since panNETs often metastasize to the liver [1]. Importantly, in 80% of all newly diagnosed panNETs multiple liver and/or extrahepatic metastases are detected [4,5].

For tumor located in the pancreatic head a pancreaticoduodenectomy is performed in most cases. In contrast, for tumors located in the pancreatic tail a distal pancreatectomy is the surgical procedure of choice. Although a surgical approach is considered whenever a malignant, resectable and non-metastasized tumor is suspected, histopathological examinations ultimately reveal a benign diagnosis in 5–21% upon pancreaticoduodenectomies and 11% upon distal pancreatectomies [6–9].

2. Case report

We report on a 49-year-old woman with benign kidney cysts. No additional preconditions were known and the patient was not under any long-term medication. The patient underwent a follow-up MRI because of kidney cysts in 03/2014. Here, a tumor in the pancreatic tail was identified which initially showed characteristic of a benign lesion. In a subsequent MRI performed in 10/2014 the lesion had increased in size and now presented with some radiological features of a malignant tumor (Fig. 1). Therefore the patient was admitted to our hospital for further examination. The patient was asymptomatic and routine laboratory analysis did not show any pathology, including normal CA 19-9. To further characterize the pancreatic lesion a computed tomography (CT) of the abdomen was performed. Here, the lesion showed radiological characteristics of a neuroendocrine tumor (Fig. 2). Moreover, the CT scan revealed a contrast-enhanced lesion of the liver for which malignancy could not be excluded (Fig. 3).

In a subsequently performed endosonography the pancreas showed no pathological signs and the pancreatic lesion could not be identified excluding the possibility to obtain a biopsy. To further characterize the pancreatic tumor a Dotatate PET-CT was performed which revealed strong Tracer-uptake of the pancreatic lesion, strongly suggesting a neuroendocrine tumor of the pancreatic tail (Fig. 4). Subsequently, the patient underwent spleen-preserving distal pancreatectomy and atypical liver resection. Intraoperatively, the tumor presented as a soft lesion of dark

* Corresponding author. Fax: +49 731 500 53503.

E-mail address: doris.henne-bruns@uniklinik-ulm.de (D. Henne-Brunns).




Fig. 1. Arterial phase of a T1 weighted MRI showing an inhomogeneous contrast enhancement of a suspect lesion of the pancreatic tail.




Fig. 2. Arterial phase of a contrast-enhanced CT scan. Intrapancreatic tumor (arrow) showing inhomogeneous contrast enhancement.




Fig. 3. Arterial phase of a contrast-enhanced CT scan showing contrast enhancement (arrow) of a liver lesion.

color. Interestingly, intraoperatively performed histopathological examination did not show malignant features of the pancreatic tumor, which was the reason why the spleen was preserved.

The postoperative course of the patient was uneventful. Surprisingly, the histopathological analysis revealed the pancreatic lesion being an intrapancreatic accessory spleen ([Fig. 5](#)) and the liver lesion being a hemangioma.

3. Discussion

Accessory spleens originate from a congenital failure of splenic bud fusion during embryogenesis [\[10\]](#). This abnormality is detected in about 10–30% in autopsies. In most cases accessory spleens are located at the splenic hilum. Interestingly, CT scans reveal asymptomatic accessory spleens in 16% of patients undergoing CT scans of the abdomen [\[11,12\]](#). Although, intrapancreatic accessory spleens can mimic intrapancreatic tumors, such as neuroendocrine tumors




Fig. 4. Dotatate PET-CT showing strong Tracer uptake in the suspect lesion of the pancreatic tail.




Fig. 5. Histopathology of the resected pancreatic tissue: HE (A) staining suggesting an intrapancreatic accessory spleen, B: immunohistopathological CD20 (B) and CD3 (C) staining confirming the benign diagnose of an accessory spleen of the pancreatic tail.

[13], up to date only a few cases of non-cystic intrapancreatic accessory spleen have been reported in the literature.

In cases of panNETs presenting with synchronous liver metastases surgery is usually considered in cases when complete surgical resection of the primary tumor and the metastatic lesions appears feasible. In contrast, the diagnosis of asymptomatic IPAS does not require a surgical treatment [1,2]. This fact underlines the crucial necessity to provide adequate preoperative diagnostics to prevent patients from unnecessary surgery.

In the presented case a metastatic panNET was suspected pre-operatively based on the MRI and CT scan as well as on a Dotatate PET-CT, which lead to unnecessary distal pancreatectomy.

Interestingly it has been reported that IPAS can mimic panNET in nuclear imaging, such as Dotatate PET-CT, due to somatostatin-positivity of intrasplenic lymphocytes [15]. Non-invasive differentiation between IPAS and panNET can be provided by using ^{99m}Tc -sulphur-colloid or ^{99m}Tc -tagged heat-damaged RBC Scintigraphy, due to selective phagocytosis by reticulum-endothelial cells in the liver and spleen [16,17].

Furthermore the suspected diagnosis of panNET was hardened by CT-imaging, which showed a contrast-enhanced lesion of the liver, for which malignancy could not be ruled out, which finally lead to atypical liver resection. Postoperatively the histopathological analysis revealed a liver hemangioma. Interestingly, it has been

reported that sclerosed hemangioma can mimic liver metastasis of gastrointestinal cancers [14].

In conclusion, we consider IPAS a relevant differential diagnosis in patients with suspected panNET, which should be taken into account before surgery is provided.

Conflicts of interest

All authors declare no conflict of interest.

Funding

There was no funding for this study.

Ethical approval

Not applicable.

Author contribution

C.C.E., M.K. and D.H.-B. designed the study. C.C.E and J.L. performed the research and wrote the manuscript. T.F.B. provided pathological analysis. S.A.S. provided radiological analysis. All authors read and approved the manuscript.

Consent

Not applicable.

Guarantor

Prof. Doris Henne-Brunns.

References

- [1] M.D. Reid, S. Balci, B. Saka, N.V. Adsay, Neuroendocrine tumors of the pancreas: current concepts and controversies, *Endocr. Pathol.* 25 (2014) 65–79.
- [2] P.A. Vagefi, O. Razo, V. Deshpande, D.J. McGrath, G.Y. Lauwers, S.P. Thayer, A.L. Warshaw, C. Fernández-Del Castillo, Evolving patterns in the detection and outcomes of pancreatic neuroendocrine neoplasms: the Massachusetts General Hospital experience from 1977 to 2005, *Arch. Surg.* 142 (2007) 347–354.
- [3] H. Dralle, S.L. Krohn, W. Karges, B.O. Boehm, M. Brauckhoff, O. Gimm, Surgery of resectable nonfunctioning neuroendocrine pancreatic tumors, *World J. Surg.* 28 (2004) 1248–1260.
- [4] W. Kimura, K. Tezuka, I. Hirai, Surgical management of pancreatic neuroendocrine tumors, *Surg. Today* 41 (2011) 1332–1343.
- [5] T. Hori, K. Takaori, S. Uemoto, Pancreatic neuroendocrine tumor accompanied with multiple liver metastases, *World J. Hepatol.* 6 (2014) 596–600.
- [6] S.A. Barends, K.D. Lillemoen, H.S. Kaufman, P.K. Sauter, C.J. Yeo, M.A. Talamini, H.A. Pitt, J.L. Cameron, Pancreaticoduodenectomy for benign disease, *Am. J. Surg.* 171 (1996) 131–134, Discussion 134–135.
- [7] N.V. Adsay, O. Basturk, D.S. Klimstra, G. Klöppel, Pancreatic pseudotumors: non-neoplastic solid lesions of the pancreas that clinically mimic pancreas cancer, *Semin. Diagn. Pathol.* 21 (2004) 260–267.
- [8] M.G. Hurtuk, M. Shoup, K. Oshima, S. Yong, G.V. Aranha, Pancreaticoduodenectomies in patients without periampullary neoplasms: lesions that masquerade as cancer, *Am. J. Surg.* 199 (2010) 372–376, Discussion 376.
- [9] F. Vitali, T. Hansen, R. Kiesslich, S. Heinrich, A. Kumar, P. Mildenberger, A. Amodio, L. Benini, I. Vantini, L. Frulloni, Frequency and characterization of benign lesions in patients undergoing surgery for the suspicion of solid pancreatic neoplasm, *Pancreas* 43 (2014) 1329–1333.
- [10] W.J. Dodds, A.J. Taylor, S.J. Erickson, E.T. Stewart, T.L. Lawson, Radiologic imaging of splenic anomalies, *AJR* 155 (1990) 805–810.
- [11] A.J. Eraklis, R.M. Filler, Splenectomy in childhood: a review of 1413 cases, *J. Pediatr. Surg.* 7 (1972) 382–388.
- [12] K.J. Mortelé, B. Mortelé, S.G. Silverman, CT features of the accessory spleen, *AJR Am. J. Roentgenol.* 183 (2004) 1653–1657.
- [13] A. Kurmann, J.-M. Michel, E. Stauffer, B. Egger, Intrapancreatic accessory spleen misdiagnosed as a nonsecreting endocrine tumor: case report and review of the literature, *Case Rep. Gastroenterol.* 4 (2010) 210–214.
- [14] S. Yamada, M. Shimada, T. Utsunomiya, Y. Morine, S. Imura, T. Ikemoto, H. Mori, J. Hanaoka, S. Iwahashi, Y. Saitoh, M. Asanoma, Hepatic sclerosed hemangioma which was misdiagnosed as metastasis of gastric cancer: report of a case, *J. Med. Invest.* 59 (2012) 270–274.
- [15] R. Lebtahi, G. Cadiot, J.P. Marmuse, C. Vissuzaine, Y. Petegnief, A. Courillon-Mallet, D. Cattan, M. Mignon, D. Le Guludec, False-positive somatostatin receptor scintigraphy due to an accessory spleen, *J. Nucl. Med.* 38 (1997) 1979–1981.
- [16] L.E. Brasca, A. Zanello, A. De Gaspari, F. De Cobelli, A. Zerbi, F. Fazio, A. Del Maschio, Intrapancreatic accessory spleen mimicking a neuroendocrine tumor: magnetic resonance findings and possible diagnostic role of different nuclear medicine tests, *Eur. Radiol.* 14 (2004) 1322–1323.
- [17] L.A. Spencer, D.L. Spizarny, T.R. Williams, Imaging features of intrapancreatic accessory spleen, *Br. J. Radiol.* 83 (2010) 668–673.

Open Access

This article is published Open Access at sciencedirect.com. It is distributed under the [IJSCR Supplemental terms and conditions](#), which permits unrestricted non commercial use, distribution, and reproduction in any medium, provided the original authors and source are credited.